University of Pennsylvania - Perelman Center for Advanced Medicine
Welcome,         Profile    Billing    Logout  
 18 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vose, Julie M
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05976763: Testing Continuous Versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma

Recruiting
3
421
US
Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, PET, Computed Tomography, CAT Scan, CT Scan, Magnetic Resonance Imaging, MRI, Esophagogastroduodenoscopy, EGD, Colonoscopy, Biospecimen Collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Mantle Cell Lymphoma
08/38
08/38
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
SGN35C-001, NCT06254495: A Safety Study of SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
SGN-35C
Seagen Inc.
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
02/28
08/28
NCT03964480: Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

Recruiting
N/A
1000
Europe, US, RoW
Associazione Angela Serra per la ricerca sul cancro
Peripheral T-Cell Lymphoma
01/23
07/25
NCT02553447: Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency

Active, not recruiting
N/A
197
US
Cholecalciferol, 9,10-Secocholesta-5,7,10(19)-trien-3-ol, Calciol, Delsterol, Vitamin D3, Laboratory Biomarker Analysis
University of Nebraska, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Untreated Chronic Lymphocytic Leukemia, Vitamin D Deficiency
03/25
03/25
Vogl, Dan
iinnovate-1, NCT03215030 / 2021-006038-37: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Completed
1/2
272
Europe, Canada, Japan, US, RoW
Modakafusp alfa, TAK-573, TEV-48573, Dexamethasone
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
07/24
11/24
NCT04405167: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Recruiting
1
34
US
Tasquinimod, IRd chemotherapy, Ixazomib, Lenalidomide, Dexamethasone
University of Pennsylvania, Active Biotech AB
Multiple Myeloma
07/25
07/26
iinnovate-2, NCT05556616 / 2022-001418-20: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Completed
1
15
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda, Takeda Development Center Americas, Inc.
Multiple Myeloma
06/24
06/24
NCT01985919: Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

Recruiting
N/A
150
US
Obtaining human tissue for basic research or biospecimen bank
Abramson Cancer Center at Penn Medicine
No Restrictions on Diagnosis
05/25
05/25
Kim, Lyndon
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Desai, Arati
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT02847559: Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Recruiting
2
27
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Electric Field Therapy, NovoTTF-200A Device, NovoTTF-200A, NovoTTF-200A System, NovoTTFields, NovoTumor Treatment Fields, Optune, Optune Device, Quality-of-Life Assessment, Quality of Life Assessment
Northwestern University, NovoCure Ltd., National Cancer Institute (NCI)
Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
09/26
12/26
A071401, NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas

Recruiting
2
124
US
Vismodegib, GDC-0449, FAK Inhibitor GSK2256098, Capivasertib, AZD5363, Abemaciclib
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
01/26
01/28
Karam, Chafic
NCT04146051: Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Recruiting
2
30
Canada, US
Descartes-08
Cartesian Therapeutics
Myasthenia Gravis, Generalized
03/25
03/26
CASCA, NCT06798012: A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Not yet recruiting
2
36
US
TAK-411, Hypersialylated Immune Globulin G
Takeda
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
12/27
06/28
ARDA+, NCT05405361 / 2021-004998-32: A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults with Multifocal Motor Neuropathy

Active, not recruiting
2
51
Europe, Canada, US
ARGX-117, Placebo
argenx, argenx BV
Multifocal Motor Neuropathy (MMN)
09/26
09/26
NCT05701189: Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome

Recruiting
2
30
US
Efgartigimod Alfa-Fcab, Vyvgart, Intravenous Immunoglobulin (IVIg)
Chafic Karam, argenx
Guillain-Barre Syndrome
08/26
05/27
EDONA, NCT05311488: Early Detection of Neuropathy in ATTRv

Active, not recruiting
N/A
47
US
neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
University of Pennsylvania, Ionis Pharmaceuticals, Inc., AstraZeneca
Hereditary Amyloidosis, Transthyretin-Related
06/25
02/29
EPIPHANY, NCT03997981: Chemotherapy Induced Peripheral Neuropathy Natural History Study

Recruiting
N/A
200
US
Disarm Therapeutics, Eli Lilly and Company
Chemotherapy-induced Peripheral Neuropathy
03/24
04/24
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

Recruiting
N/A
150
Europe, Canada, Japan, US, RoW
argenx
Multifocal Motor Neuropathy
11/25
11/25
Johnson, Debbie
ProSTAR, NCT03480646: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Hourglass Apr 2020 - Sep 2020 : Updated data from P1/2 ProSTAR trial for mCRPC
Checkmark Data from P1b portion of P1b/2 ProSTAR trial for mCRPC at AACR 2019 [screenshot]
Apr 2019 - Apr 2019: Data from P1b portion of P1b/2 ProSTAR trial for mCRPC at AACR 2019 [screenshot]
Checkmark From ProSTAR trial in metastatic prostate cancer [screenshot]
May 2018 - May 2018: From ProSTAR trial in metastatic prostate cancer [screenshot]
Active, not recruiting
1b/2
242
US
CPI-1205, Enzalutamide, Abiraterone/Prednisone
Constellation Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer (mCRPC)
12/21
12/21
VERU-100, NCT04843319: To Determine an Effective Dose of for the Treatment of Advanced Prostate Cancer

Terminated
1b/2
24
US
VERU-100
Veru Inc.
Advanced Prostate Adenocarcinoma
01/23
01/23
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
Evans, Tamara K
ANDECAL, NCT06508021: A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Recruiting
2/3
92
US
Andecaliximab, Placebo
Ashibio Inc
Fibrodysplasia Ossificans Progressiva
02/29
02/29
AFFIRM, NCT03430037: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women

Enrolling by invitation
2
40
US
Fisetin, Placebo oral capsule, Placebo
Mayo Clinic
Frail Elderly Syndrome
10/25
10/25
AFFIRM-LITE, NCT03675724: Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

Enrolling by invitation
2
40
US
Fisetin, Placebo oral capsule
Mayo Clinic
Frail Elderly Syndrome
10/25
10/25
NCT04903132: Cellular Senescence and COVID-19 Long-Hauler Syndrome

Enrolling by invitation
N/A
200
US
Mayo Clinic
SARS-CoV2 Infection
12/24
12/24
Bargo, Alicia
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
NCT04617002: Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Available
N/A
US
ONC201 (dordaviprone)
Chimerix
Glioma, H3 K27M
 
 
Myers, Lindsey
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
McCoy, Emily
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Torres, Denisse
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
Lind, Ashley
ANDECAL, NCT06508021: A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Recruiting
2/3
92
US
Andecaliximab, Placebo
Ashibio Inc
Fibrodysplasia Ossificans Progressiva
02/29
02/29

Download Options